carnitine has been researched along with Dyslipidemia in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine deficiency is a commonly observed problem in maintenance hemodialysis (MHD) patients, which results in altered metabolism of fatty acids and subsequently development of dyslipidemia." | 9.16 | Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. ( Harandi, AA; Moghadasi, M; Mortazavi, M; Naini, AE; Sadeghi, M, 2012) |
| "L-Carnitine is a critical metabolite indispensable for the metabolism of lipids as it facilitates fatty acid transport into the mitochondrion where β-oxidation occurs." | 5.37 | The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. ( Appanna, VD; Auger, C; Darwich, R; Lemire, J; Mailloux, R, 2011) |
| "Carnitine deficiency is a commonly observed problem in maintenance hemodialysis (MHD) patients, which results in altered metabolism of fatty acids and subsequently development of dyslipidemia." | 5.16 | Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients. ( Harandi, AA; Moghadasi, M; Mortazavi, M; Naini, AE; Sadeghi, M, 2012) |
| "Carnitine is an amino acid derivative that has a key role in the regulation of fatty acid metabolism and ATP formation." | 2.43 | The use of levo-carnitine in children with renal disease: a review and a call for future studies. ( Belay, B; Esteban-Cruciani, N; Kaskel, FJ; Walsh, CA, 2006) |
| "In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1." | 1.62 | Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. ( Bönhof, GJ; Knebel, B; Kotzka, J; Roden, M; Straßburger, K; Strom, A; Szendroedi, J; Ziegler, D, 2021) |
| "L-Carnitine is a critical metabolite indispensable for the metabolism of lipids as it facilitates fatty acid transport into the mitochondrion where β-oxidation occurs." | 1.37 | The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. ( Appanna, VD; Auger, C; Darwich, R; Lemire, J; Mailloux, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, Y | 1 |
| Sun, Y | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Zeng, R | 1 |
| Lin, X | 1 |
| Li, Y | 1 |
| Ziegler, D | 1 |
| Strom, A | 1 |
| Straßburger, K | 1 |
| Knebel, B | 1 |
| Bönhof, GJ | 1 |
| Kotzka, J | 1 |
| Szendroedi, J | 1 |
| Roden, M | 1 |
| Duta-Mare, M | 1 |
| Sachdev, V | 1 |
| Leopold, C | 1 |
| Kolb, D | 1 |
| Vujic, N | 1 |
| Korbelius, M | 1 |
| Hofer, DC | 1 |
| Xia, W | 1 |
| Huber, K | 1 |
| Auer, M | 1 |
| Gottschalk, B | 1 |
| Magnes, C | 1 |
| Graier, WF | 1 |
| Prokesch, A | 1 |
| Radovic, B | 1 |
| Bogner-Strauss, JG | 1 |
| Kratky, D | 1 |
| Higashimoto, M | 1 |
| Isoyama, N | 1 |
| Ishibashi, S | 1 |
| Ogawa, N | 1 |
| Takiguchi, M | 1 |
| Suzuki, S | 1 |
| Ohnishi, Y | 1 |
| Sato, M | 1 |
| Zhou, P | 1 |
| Zhang, J | 1 |
| He, N | 1 |
| Chang, G | 1 |
| Li, J | 1 |
| Gu, Q | 1 |
| Salmanoglu, DS | 1 |
| Gurpinar, T | 1 |
| Vural, K | 1 |
| Ekerbicer, N | 1 |
| Darıverenli, E | 1 |
| Var, A | 1 |
| Lee, J | 1 |
| Choi, J | 1 |
| Scafidi, S | 1 |
| Wolfgang, MJ | 1 |
| Galvano, F | 1 |
| Li Volti, G | 1 |
| Malaguarnera, M | 2 |
| Avitabile, T | 1 |
| Antic, T | 1 |
| Vacante, M | 1 |
| Lemire, J | 1 |
| Mailloux, R | 1 |
| Darwich, R | 1 |
| Auger, C | 1 |
| Appanna, VD | 1 |
| Naini, AE | 1 |
| Sadeghi, M | 1 |
| Mortazavi, M | 1 |
| Moghadasi, M | 1 |
| Harandi, AA | 1 |
| Belay, B | 1 |
| Esteban-Cruciani, N | 1 |
| Walsh, CA | 1 |
| Kaskel, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low-Carbohydrate or Restricted-Calories Diet on Body Weight[NCT01358890] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carnitine and Dyslipidemia
| Article | Year |
|---|---|
The use of levo-carnitine in children with renal disease: a review and a call for future studies.
Topics: Anemia; Carnitine; Child; Dyslipidemias; Humans; Kidney Diseases; Kidney Failure, Chronic; Stereoiso | 2006 |
3 trials available for carnitine and Dyslipidemia
| Article | Year |
|---|---|
Effects of gut microbiota and fatty acid metabolism on dyslipidemia following weight-loss diets in women: Results from a randomized controlled trial.
Topics: Adult; Caloric Restriction; Carnitine; Diet, Carbohydrate-Restricted; Diet, Reducing; Dyslipidemias; | 2021 |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Topics: Apoprotein(a); Blood Glucose; Body Mass Index; Carnitine; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2009 |
Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
Topics: Administration, Oral; Adult; Aged; Carnitine; Cholesterol; Dietary Supplements; Dyslipidemias; Femal | 2012 |
7 other studies available for carnitine and Dyslipidemia
| Article | Year |
|---|---|
Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes.
Topics: Adult; Autonomic Nervous System Diseases; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 2021 |
Lysosomal acid lipase regulates fatty acid channeling in brown adipose tissue to maintain thermogenesis.
Topics: Acetyl Coenzyme A; Adipocytes, Brown; Adipose Tissue, Brown; Animals; Autophagy; Body Temperature; C | 2018 |
Preventive effects of metallothionein against DNA and lipid metabolic damages in dyslipidemic mice under repeated mild stress.
Topics: Adiponectin; Animals; Carnitine; Corticosterone; Diet, High-Fat; DNA Damage; Dyslipidemias; Female; | 2013 |
[Study on the correlation between serum lipid and serum carnitine palmitoyl transferase 1A in rural adults over 40 years in Tianjin].
Topics: Adult; Carnitine; Carnitine O-Palmitoyltransferase; China; Cholesterol; Cholesterol, HDL; Dyslipidem | 2014 |
Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in Type 2 diabetic rats.
Topics: Animals; Antioxidants; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, | 2016 |
Hepatic Fatty Acid Oxidation Restrains Systemic Catabolism during Starvation.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carnitine; Carnitine O-Palmitoyltransferase; Di | 2016 |
The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells.
Topics: Aluminum; Astrocytes; Carnitine; Cell Line, Tumor; Dyslipidemias; gamma-Butyrobetaine Dioxygenase; H | 2011 |